IL13 and Increased total eosinophil count: Similarly, there is little evidence that dupilumab, which decreases tissue eosinophilia and blocks IL-4 and IL-13 signaling, adversely affects tissue repair, despite a growing body of evidence pointing to the importance of eosinophil secretion of IL-4 in this process109.